| 1 | Signatures of mutational processes in human cancer | Nature | 2013 | 7,134 |
| 2 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | JAMA - Journal of the American Medical Association | 2017 | 2,141 |
| 3 | Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial | Lancet Oncology, The | 2015 | 1,919 |
| 4 | Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer | Lancet, The | 2005 | 1,810 |
| 5 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | Nature | 2016 | 1,620 |
| 6 | Genome-wide association study identifies novel breast cancer susceptibility loci | Nature | 2007 | 1,549 |
| 7 | Mutational Processes Molding the Genomes of 21 Breast Cancers | Cell | 2012 | 1,390 |
| 8 | Genes that mediate breast cancer metastasis to the brain | Nature | 2009 | 1,365 |
| 9 | The landscape of cancer genes and mutational processes in breast cancer | Nature | 2012 | 1,194 |
| 10 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Lancet, The | 2004 | 1,143 |
| 11 | Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition | New England Journal of Medicine | 2004 | 1,073 |
| 12 | Association analysis identifies 65 new breast cancer risk loci | Nature | 2017 | 1,042 |
| 13 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group | Annals of Oncology | 2020 | 892 |
| 14 | Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ | Annals of Oncology | 2021 | 859 |
| 15 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Nature Genetics | 2013 | 800 |
| 16 | HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures | Nature Medicine | 2017 | 757 |
| 17 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | American Journal of Human Genetics | 2019 | 755 |
| 18 | Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience | Journal of Clinical Oncology | 2006 | 658 |
| 19 | Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation | New England Journal of Medicine | 2001 | 623 |
| 20 | Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer | Journal of the National Cancer Institute | 2007 | 604 |
| 21 | Complex landscapes of somatic rearrangement in human breast cancer genomes | Nature | 2009 | 595 |
| 22 | Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity | Molecular Therapy | 2013 | 561 |
| 23 | Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction | PLoS ONE | 2010 | 543 |
| 24 | Genomic Evolution of Breast Cancer Metastasis and Relapse | Cancer Cell | 2017 | 515 |
| 25 | Genome-wide association study identifies five new breast cancer susceptibility loci | Nature Genetics | 2010 | 511 |
| 26 | Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2022 | 485 |
| 27 | Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals | Cancer Cell | 2009 | 484 |
| 28 | CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer | Genome Research | 2013 | 448 |
| 29 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Nature Genetics | 2015 | 445 |
| 30 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk | Nature Genetics | 2017 | 423 |
| 31 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche | Nature | 2014 | 415 |
| 32 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Nature Genetics | 2013 | 407 |
| 33 | Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 383 |
| 34 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer | JAMA - Journal of the American Medical Association | 2015 | 382 |
| 35 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | Nature Genetics | 2017 | 374 |
| 36 | Pan-cancer landscape of homologous recombination deficiency | Nature Communications | 2020 | 371 |
| 37 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up | Annals of Oncology | 2019 | 369 |
| 38 | Pharmacological Effects of Formulation Vehicles | Clinical Pharmacokinetics | 2012 | 358 |
| 39 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 | Nature Genetics | 2009 | 354 |
| 40 | Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences | Drugs | 2020 | 344 |
| 41 | A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study | Lancet Oncology, The | 2017 | 343 |
| 42 | European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I | European Urology | 2008 | 340 |
| 43 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses | Nature Genetics | 2020 | 335 |
| 44 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics | Clinical Pharmacokinetics | 2018 | 331 |
| 45 | Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes | PLoS ONE | 2014 | 320 |
| 46 | Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy | Nature Medicine | 2010 | 317 |
| 47 | Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group | European Journal of Cancer | 2004 | 315 |
| 48 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair | Nature Genetics | 2015 | 312 |
| 49 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Nature Genetics | 2017 | 309 |
| 50 | Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma | Cell | 2013 | 308 |
